Myeloid tissue

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

Retrieved on: 
Thursday, April 4, 2024
Vivo, Canadian Aviation Regulations, Patient, Primate, RNA, Fragment crystallizable region, Cancer, Messenger, AACR, Chemokine, Cytokine, Drug development, Safety, Myeloid tissue, NK, LNP, Antigen, Annual general meeting, Vaccine

This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.

Key Points: 
  • This advancing study represents the first human trial of any in vivo chimeric antigen receptor (CAR) therapy.
  • Myeloid will also share information on its portfolio of immune cell programming CARs.
  • "We are thrilled to continue driving this first in vivo mRNA CAR program forward," said Chief Executive Officer Daniel Getts, Ph.D. "Myeloid is at the forefront of in vivo immune cell programming.
  • To date, Myeloid has demonstrated CAR activity in human cells, and following systemic mRNA/LNP delivery in mouse and non-human primates.

Myeloid Therapeutics to Provide Updates on its RNA Immunotherapies at Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024
Annual general meeting, Myeloid tissue, Therapy, AACR

CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, at the San Diego Convention Center.

Key Points: 
  • CAMBRIDGE, Mass., March 5, 2024 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage immunology company, today announced it will be providing updates on its RNA immunotherapies at multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, at the San Diego Convention Center.

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

Retrieved on: 
Monday, January 15, 2024
Community, NGS, Patient, Research, Partnership, Radiation, Algorithm, Skin, Cancer, GENETICS, Brain, Laboratory, Bone marrow, Sophia Genetics, Breast, Lung, Myeloid tissue, Prostate, Diagnosis, Medicine, Pancreas, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, Jan. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer testing and research for blood cancers and solid tumors to underserved areas in low and middle-income countries.

Key Points: 
  • Karkinos Healthcare is a purpose-driven, technology-led oncology platform, focused on early detection, advanced diagnostics, and treatment delivery of common cancers, using its Distributed Cancer Care Network across India.
  • On this strategic partnership, Dr. R Venkataramanan, Founder and CEO, Karkinos Healthcare said, "Through collaborative research initiatives, Karkinos Healthcare aims to address the comprehensive genomic landscape identification for Indian population, with a focus on precision medicine.
  • Karkinos Healthcare will use SOPHiA GENETICS' technology to expand its offerings, advance research and streamline workflow for a variety of blood cancers, including Myeloid cancer and Lymphoma.
  • By using the SOPHiA DDM™ Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine.

SOPHiA GENETICS and Karkinos Healthcare Forge Strategic Partnership to Advance Cancer Research in India

Retrieved on: 
Monday, January 15, 2024
Community, NGS, Patient, Research, Partnership, Radiation, Algorithm, Skin, Cancer, GENETICS, Brain, Laboratory, Bone marrow, Sophia Genetics, Breast, Lung, Myeloid tissue, Prostate, Diagnosis, Medicine, Pancreas, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, Jan. 14, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Karkinos Healthcare, a purpose-driven cancer care technology network based in India, will partner with SOPHiA GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer testing and research for blood cancers and solid tumors to underserved areas in low and middle-income countries.

Key Points: 
  • Karkinos Healthcare is a purpose-driven, technology-led oncology platform, focused on early detection, advanced diagnostics, and treatment delivery of common cancers, using its Distributed Cancer Care Network across India.
  • On this strategic partnership, Dr. R Venkataramanan, Founder and CEO, Karkinos Healthcare said, "Through collaborative research initiatives, Karkinos Healthcare aims to address the comprehensive genomic landscape identification for Indian population, with a focus on precision medicine.
  • Karkinos Healthcare will use SOPHiA GENETICS' technology to expand its offerings, advance research and streamline workflow for a variety of blood cancers, including Myeloid cancer and Lymphoma.
  • By using the SOPHiA DDM™ Platform, researchers from Karkinos Healthcare will quickly obtain high-quality and reproducible data that will ultimately accelerate clinical research studies and advance the use of precision medicine.

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Retrieved on: 
Saturday, January 6, 2024
Patient, RNA, Medical Subject Headings, Liver, Marketing, INN, Risk, Classification, Bone marrow, ATC, IPSS, International, WHO, B cell, Myeloid tissue, Azacitidine, Myelodysplastic syndrome, CMML, DNA, Nausea, Blood, Language, MDS, Cancer, Abdomen, Death, Myelocyte, European Medicines Agency, Syndrome, Monocyte, Thigh, Growth, Select, HSCT, Anatomy, AML, Pancreatic serous cystadenoma, Acute leukemia, IIA, Skin, Cytidine, Vomiting, Medical device

Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Azacitidine Accord, azacitidine, Date of authorisation: 13/02/2020, Revision: 7, Status: Authorised

Prime Medicine and Myeloid Therapeutics Announce Settlement of Pending Disputes

Retrieved on: 
Friday, January 5, 2024
Patient, Myeloid tissue

CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ -- Prime Medicine, Inc. (Nasdaq: PRME) ("Prime Medicine") and Myeloid Therapeutics, Inc. ("Myeloid"), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a positive outcome for both parties.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 5, 2024 /PRNewswire/ -- Prime Medicine, Inc. (Nasdaq: PRME) ("Prime Medicine") and Myeloid Therapeutics, Inc. ("Myeloid"), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a positive outcome for both parties.
  • "I am happy we have reached an amicable settlement with Myeloid.
  • We believe resolving this dispute is in the best interest of our shareholders and allows each company to pursue its goals of developing differentiated, potentially curative therapies for patients," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine.
  • Dr. Daniel Getts, Chief Executive Officer of Myeloid Therapeutics, commented, "Our collaboration with Prime Medicine has been characterized by mutual respect and a shared commitment to innovation.

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Liver, Marketing, INN, Risk, Leukopenia, Woman, Nausea, DNA, Cancer, Death, Anatomy, Pancreatic serous cystadenoma, IIA, CHMP, Skin, Bone marrow, ATC, IPSS, Myeloid tissue, European, Ageing, MDS, Abdomen, Kidney, Neutrophil, Blood, Syndrome, Thigh, Patient, RNA, Medical Subject Headings, European Commission, WHO, B cell, International, Neutropenia, Language, CMML, Myelodysplastic syndrome, Thrombocytopenia, Monocyte, Select, HSCT, Medicine, Vomiting, Cytidine, Survival, Classification, Stomach, Myelocyte, Growth, Committee, AML, Acute leukemia, Medical device

Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vidaza, azacitidine, Date of authorisation: 17/12/2008, Revision: 27, Status: Authorised

Myeloid Announces Appointment of Matthew Maurer, M.D. as Chief Medical Officer

Retrieved on: 
Wednesday, December 6, 2023
Renal cell carcinoma, Assistant, Bristol Myers Squibb, Therapy, Mechanical engineering, IND, Physician, Mount Sinai School, Biotechnology, Breast cancer, Patient, Medical Affairs Bureau, Myeloid-derived suppressor cell, Princeton University, Messenger, BSE, PARG, Myeloid tissue, Cancer, BMS, Immunotherapy, Mechanical, Pharmaceutical industry, Surgeon, Medicine, Vivo

CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.

Key Points: 
  • CAMBRIDGE, Mass., Dec. 6, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage oncology company, has appointed Matthew Maurer, M.D.
  • as Chief Medical Officer.
  • "We are very pleased that Matt has joined Myeloid as our Chief Medical Officer.
  • Dr. Maurer received a BSE in Mechanical Engineering from Princeton University and earned his medical degree from the Mount Sinai School of Medicine.

Myeloid Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
Monday, October 2, 2023
Myeloid tissue, Therapy, Conference, Pharmaceutical industry

CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences:

Key Points: 
  • CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences:
    Chardan's 7th Annual Genetic Medicines Conference, taking place October 2-3, 2023, in NY
    3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, taking place October 17-18, 2023

Myeloid Therapeutics to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, August 31, 2023
Myeloid tissue, Citigroup, Therapy, Conference, Pharmaceutical industry, Cryptocurrency

CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences:

Key Points: 
  • CAMBRIDGE, Mass., Aug. 31, 2023 /PRNewswire/ -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical stage mRNA-immunotherapy company, today announced that it will participate in the following investor conferences:
    Citi's 18th Annual BioPharma Conference, taking place September 5-7, 2023, in Boston, MA
    Management will participate in a fireside chat on September 6, 2023, at 11:20 am ET.
  • Management will participate in a panel titled "Immune Cell Engineering" on September 12, 2023, at 10:15 am PT.
  • Morgan Stanley 21st Annual Global Healthcare Conference, taking place September 11-13, 2023, in NY